Shifting From Spending to Saving For Young Investors
Before investors focus on preserving wealth in retirement, they first navigate an earlier transition: shifting from spending to saving and investing.
Read more
A New Model For Retirement Care
As healthcare moves beyond hospitals and into patients’ homes, how are new technologies and care models helping adults maintain independence while reshaping the retirement experience?
Read more
How Women Are Shaping the Future of Philanthropy
As women’s influence over wealth grows, so does their impact on philanthropy—bringing a more intentional, values-driven approach to giving across generations.
Read more
William Blair Thinking
Our Mission, Vision, and Values
At William Blair, we're committed to our colleagues, our clients, and our communities. Serving our clients starts with the capabilities and collaboration of our team—making our employees our most important asset. When we create an environment where employees perform their best, our delivery for clients will be the best it can be.
Learn more about our mission, vision, and values
Global Community Partners
We are proud of our signature Global Community Partners program, through which employees nominate organizations to receive catalytic financial support and significant volunteerism opportunities every two years.
More about our community partners
Our Latest News
-
Beta Bionics, Inc. and Tandem Diabetes Care, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Beta Bionics, Inc. (BBNX $20.01) and Tandem Diabetes Care, Inc. (TNDM $23.46), medical technology companies that develop, manufacture, and market automated insulin delivery systems for the management of diabetes.
-
Surrozen, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Surrozen, Inc. (SRZN $24.00), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions.
-
Enliven Therapeutics, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Enliven Therapeutics, Inc. (ELVN $58.82), a late-stage biotech focused on developing ELVN-001, a potent and selective tyrosine kinase inhibitor (TKI), for the treatment of chronic myeloid leukemia (CML).
Join Our Team
Finding, attracting, and developing talented people is the foundation of our success. Learn about the promising career opportunities currently available at William Blair.
Search our job openings
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights